Budget Impact Analysis of Ixabepilone Used According to FDA Approved Labeling in Treatment-Resistant Metastatic Breast Cancer

BACKGROUND: Breast cancer is one of the most common forms of cancer in the United States, with approximately 10% of newly diagnosed patients presenting with metastatic disease. Limited therapy options make the successful treatment of metastatic breast cancer (MBC) difficult. Current treatment option...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Joanne, Zhang, Lihua, Todorova, Lora, Whillans, Finlay, Corey-Lisle, Patricia, Yuan, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2009
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437736/
https://www.ncbi.nlm.nih.gov/pubmed/19610679
http://dx.doi.org/10.18553/jmcp.2009.15.6.467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437736/
https://www.ncbi.nlm.nih.gov/pubmed/19610679
http://dx.doi.org/10.18553/jmcp.2009.15.6.467

Ejemplares similares